Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Investing Activities (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Cash from Investing Activities for 8 consecutive years, with -$674000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities fell 54.94% year-over-year to -$674000.0, compared with a TTM value of -$2.1 million through Sep 2025, down 133.55%, and an annual FY2024 reading of -$1.2 million, up 57.84% over the prior year.
  • Cash from Investing Activities was -$674000.0 for Q3 2025 at Bicycle Therapeutics, down from -$498000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$12000.0 in Q1 2024 and bottomed at -$9.8 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is -$1.4 million, with a median of -$502000.0 recorded in 2023.
  • The sharpest move saw Cash from Investing Activities tumbled 5630.41% in 2022, then surged 99.43% in 2024.
  • Year by year, Cash from Investing Activities stood at -$1.1 million in 2021, then crashed by 35.71% to -$1.4 million in 2022, then soared by 96.48% to -$51000.0 in 2023, then plummeted by 621.57% to -$368000.0 in 2024, then plummeted by 83.15% to -$674000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for BCYC at -$674000.0 in Q3 2025, -$498000.0 in Q2 2025, and -$604000.0 in Q1 2025.